| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
China Pharmaceutical Company Ltd.
|
911.604m | 31.53% | +1.100m | May 05 2026 |
| 2 |
Sichuan Kelun Pharmaceutical Co., Ltd.
|
680.686m | 23.54% | +1.128m | Mar 19 2026 |
| 3 |
Qu (Jiguang)
|
291.218m | 10.07% | — | May 05 2026 |
| 4 |
UBS Asset Management (Hong Kong) Limited
|
110.433m | 3.82% | +9.871m | Mar 31 2026 |
| 5 |
UBS Switzerland AG
|
61.297m | 2.12% | -13.943m | Mar 31 2026 |
|
1
China Pharmaceutical Company Ltd.
|
31.53%
911.604m
|
|
2
Sichuan Kelun Pharmaceutical Co., Ltd.
|
23.54%
680.686m
|
|
3
Qu (Jiguang)
|
10.07%
291.218m
|
|
4
UBS Asset Management (Hong Kong) Limited
|
3.82%
110.433m
|
|
5
UBS Switzerland AG
|
2.12%
61.297m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 71.08% of Ssy Group, with China Pharmaceutical Company Ltd. the biggest at 31.53%, followed by Sichuan Kelun Pharmaceutical Co., Ltd. (23.54%) and Qu (Jiguang) (10.07%). |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


